Healios K.K.

OTCPK:HLOS.F Stock Report

Market Cap: US$119.4m

Healios K.K Valuation

Is HLOS.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLOS.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLOS.F ($1.2) is trading above our estimate of fair value ($0.29)

Significantly Below Fair Value: HLOS.F is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLOS.F?

Key metric: As HLOS.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HLOS.F. This is calculated by dividing HLOS.F's market cap by their current revenue.
What is HLOS.F's PS Ratio?
PS Ratio34.8x
SalesJP¥521.00m
Market CapJP¥18.21b

Price to Sales Ratio vs Peers

How does HLOS.F's PS Ratio compare to its peers?

The above table shows the PS ratio for HLOS.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.3x
CGEN Compugen
2.3x2.3%US$126.2m
ADAP Adaptimmune Therapeutics
1x3.3%US$178.4m
CRVO CervoMed
6.5x10.9%US$72.3m
ASMB Assembly Biosciences
3.4x-44.0%US$94.1m
HLOS.F Healios K.K
34.8x43.3%US$18.2b

Price-To-Sales vs Peers: HLOS.F is expensive based on its Price-To-Sales Ratio (34.8x) compared to the peer average (3.3x).

Price to Sales Ratio vs Industry

How does HLOS.F's PS Ratio compare vs other companies in the US Biotechs Industry?

126 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.4x1.3%US$23.13b
MRNA Moderna
3.2x6.7%US$16.80b
INCY Incyte
3.5x9.0%US$14.16b
ALKS Alkermes
3.1x-0.7%US$4.75b
HLOS.F 34.8xIndustry Avg. 9.9xNo. of Companies126PS01632486480+
126 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HLOS.F is expensive based on its Price-To-Sales Ratio (34.8x) compared to the US Biotechs industry average (9.9x).

Price to Sales Ratio vs Fair Ratio

What is HLOS.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLOS.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio34.8x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HLOS.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLOS.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.20
US$2.19
+82.1%
12.7%US$2.57US$1.93n/a3
Nov ’25US$1.50
US$2.38
+58.6%
12.7%US$2.80US$2.10n/a3
Oct ’25US$1.73
US$2.38
+37.5%
12.7%US$2.80US$2.10n/a3
Sep ’25US$1.73
US$1.91
+10.2%
38.2%US$2.72US$0.95n/a3
Aug ’25n/a
US$1.79
0%
38.2%US$2.56US$0.90n/a3
Jul ’25US$1.21
US$1.79
+48.1%
38.2%US$2.56US$0.90n/a3
Jun ’25US$0.93
US$1.79
+93.6%
38.2%US$2.56US$0.90n/a3
May ’25US$0.99
US$1.85
+86.5%
38.2%US$2.64US$0.93n/a3
Apr ’25n/a
US$1.86
0%
38.2%US$2.66US$0.93n/a3
Mar ’25US$0.95
US$1.86
+96.3%
38.2%US$2.66US$0.93n/a3
Feb ’25n/a
US$1.98
0%
32.5%US$2.73US$1.16n/a3
Jan ’25n/a
US$3.71
0%
82.3%US$7.99US$1.13n/a3
Dec ’24n/a
US$3.71
0%
82.3%US$7.99US$1.13n/a3
Nov ’24n/a
US$3.73
0%
82.3%US$8.04US$1.14US$1.503
Oct ’24US$1.59
US$6.78
+327.7%
52.3%US$10.24US$1.91US$1.733
Sep ’24n/a
US$5.79
0%
61.3%US$10.29US$1.92US$1.734
Aug ’24n/a
US$5.22
0%
65.6%US$10.36US$1.93n/a5
Jul ’24n/a
US$5.22
0%
65.6%US$10.36US$1.93US$1.215
Jun ’24n/a
US$5.57
0%
65.6%US$11.05US$2.06US$0.935
May ’24n/a
US$5.58
0%
64.4%US$10.97US$2.27US$0.995
Apr ’24n/a
US$5.58
0%
64.4%US$10.97US$2.27n/a5
Mar ’24n/a
US$6.33
0%
75.9%US$14.69US$2.28US$0.955
Feb ’24n/a
US$7.12
0%
65.4%US$15.11US$2.34n/a5
Jan ’24n/a
US$7.12
0%
65.4%US$15.11US$2.34n/a5
Dec ’23n/a
US$6.74
0%
65.4%US$14.32US$2.22n/a5
Nov ’23n/a
US$6.87
0%
65.4%US$14.59US$2.26n/a5

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%